Clinical trials: Geriatric Cancer Patients
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
This is an open-label, non-randomised, multi-centre phase I-II study of CHR-2797 administered orally once a day. The study involves two distinct phases: Phase I: an open-label, dose-escalating phase of the study to explore the…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT00689000
- Testing
- CHR-2797 (tosedostat): Aminopeptidase inhibitor
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Chroma Therapeutics
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Assessing Women's Attitudes About the Risk of Infertility Related to Adjuvant Therapy for Early Breast Cancer
RATIONALE: Adjuvant therapy given after surgery for early breast cancer may cause infertility. Assessing young women's attitudes and feelings about the risk of infertility may help improve the ability to plan effective treatment.
- Conditions
- Breast Cancer, Psychosocial Effects of Cancer and Its Treatment, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues
- Trial name
- NCT00062400
- Testing
- psychosocial assessment and care
- Where
- 27 sites in Belgium, Chile and 13 more
- Volunteers
- 385 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leukemia, Myelodysplastic Syndromes
Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the cancer.
- Trial name
- NCT00516828
- Testing
- cytarabine
- Where
- 4 sites in Canada
- Volunteers
- 21 people
- Sponsor
- NCIC Clinical Trials Group
Acute Myeloid Leukemia, Adult
Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75
Patients with acute myeloid leukemia aged 65-75 have a very poor prognosis, irrespective of the treatment strategy, including demethylating agents or conventional chemotherapy.
- Trial name
- NCT03902665
- Testing
- Up-front allogeneic hematopoietic stem cell transplantation (HSCT)
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC
The aim of the trial is to evaluate the clinical benefit (efficacy, safety, preservation of autonomy) of cetuximab-carboplatin-5FU combination as first line treatment of recurrent or metastatic head and neck squamous cell…
- Trial name
- ELANFIT (NCT01864772)
- Testing
- Carbo, 5FU, Cetuximab
- Where
- 2 sites in France
- Volunteers
- 85 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Metastatic Castration-resistant Prostate Cancer (CRPCa)
Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer
This study will assess the impact of the novel oral hormonal agents (abiraterone acetate or enzalutamide) among elderly metastatic prostate cancer patients.
- Trial name
- COG-PRO (NCT02907372)
- Testing
- neuropsychologic evaluation, oncogeriatric evaluation
- Where
- 6 sites in France
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Centre Francois Baclesse
Non-Small Cell Lung Cancer
Trial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced Lung Cancer Who Are Not Eligible for Platinum-Based Chemotherapy and Have Not Previously Been Treated With Chemotherapy
This study is for elderly patients who haven't been given prior chemotherapy or for patients who cannot be treated with platinum based chemotherapy.
- Trial name
- NCT00489983
- Testing
- pemetrexed, gemcitabine
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 91 people
- Sponsor
- Eli Lilly and Company
Esophageal Cancer, Chemoradiotherapy
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
This trial is a prospective, randomized, controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of sintilimab as consolidation therapy in elderly patients with esophageal cancer who did not progress…
- Conditions
- Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy
- Trial name
- NCT06413342
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 191 people
- Sponsor
- Zhejiang Cancer Hospital
Leukemia, Myeloid, Acute, Hematologic Neoplasms
Trial of Pimasertib in Hematological Malignancies
This is an open-label, multi-center, dose-escalation trial of pimasertib (MSC1936369B) in blood and bone marrow cancers. The trial will be conducted in two parts: Part 1 (safety run-in period): Will determine the maximum…
- Trial name
- NCT00957580
- Testing
- Pimasertib
- Where
- 9 sites in United States, France
- Volunteers
- 81 people
- Sponsor
- EMD Serono
Lymphoma, Neurotoxicity
Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00666484
- Testing
- cyclophosphamide, doxorubicin hydrochloride, etoposide
- Where
- 5 sites in United Kingdom
- Volunteers
- 47 people
- Sponsor
- University College, London
Cancer, Cancer-related Problem/Condition
Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Risk Scores in Older Adults With Cancer in China
The goal of this observational study is to learn about the impact of chemotherapy-related toxicity on older cancer patients in China.
- Trial name
- NCT06717178
- Testing
- Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 360 people
- Sponsor
- RenJi Hospital
Acute Promyelocytic Leukemia
French Registry of First-line Treatment of Acute Promyelocytic Leukemia
The registry aims to compare the two first-line available treatment approaches in non-high-risk APL patients aged ≤ 70 years - ATRA plus chemotherapy and ATRA plus ATO - in terms of practitioner's choice between the two options…
- Trial name
- NCT02938858
- Where
- 27 sites in France
- Volunteers
- 400 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Metastatic Colorectal Cancer
Cetuximab for Elderly Patients With mCRC
OBJECTIVE: The objective of the trial is to judge on the benefit obtained by an upfront cetuximab treatment delivered as monotherapy or as part of a combination treatment with capecitabine in vulnerable elderly patients selected…
- Trial name
- NCT01718808
- Testing
- Cetuximab, Capecitabine
- Where
- 14 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Swiss Cancer Institute
Cancer
Impact of Oncogeriatric Consultation on Quality of Life of Patients Aged 75 and More With Cancer
Among patients with cancer, 6 in 10 are over 65 years of age. In order to improve quality of life of aged cancer patients, the oncogeriatric consultation has been created.
- Trial name
- ONCOGERIA-QDV (NCT05163015)
- Testing
- Data collection
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Université de Reims Champagne-Ardenne
Acute Myeloid Leukemia
Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML
In this prospective study, 30 newly untreated elderly patients with acute myeloid leukemia(AML) who were not suitable for standard chemotherapy were enrolled to observe the efficacy and side effects of venetoclax (VEN) combined…
- Trial name
- NCT05053425
- Testing
- Venetoclax, Azacitidine, Cladribine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- LanZhou University
Locally Advanced Cervical Carcinoma
Decision Aid for Chemotherapy in Cisplatin-Intolerant Patients With Locally Advanced Cervical Cancer
The goal of this clinical trial is to investigate the utility and effectiveness of a decision aid in cisplatin-intolerant patients with locally advanced cervical cancer. The main questions it aims to answer are: 1.
- Trial name
- CECIL (NCT05701735)
- Testing
- CECIL Patient Decision Aid
- Where
- 3 sites in Philippines
- Volunteers
- 45 people
- Sponsor
- University of Santo Tomas Hospital, Philippines
Non Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma
Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC
This Phase II trial is to see how well single agent chemotherapy and pembrolizumab work elderly patients (≥ 75 years) with advanced non small cell lung cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, PD-L1 Gene Mutation
- Trial name
- HFHS 21-01 (NCT04754815)
- Testing
- Pembrolizumab, Pemetrexed, Paclitaxel
- Sponsor
- Shirish Gadgeel
Lung Cancer
Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00541099
- Testing
- bevacizumab, docetaxel
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Small Cell Lung Cancer Extensive Stage, ELDERLY PEOPLE
Etoposide Plus Benmelstobart Followed by Maintenance Therapy of Benmelstobart Plus Anlotinib in First-line Treatment of Elderly Patients with Extensive Stage Small Cell Lung Cancer: a Single-arm, Prospective Trial
This is a prospective, single-arm clinical study to evaluate the efficacy and safety of etoposide in combination with bemosubezumab and sequential Benmelstobart in combination with Anlotinib as first-line treatment for elderly…
- Trial name
- NCT06825208
- Volunteers
- 29 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Leukemia, Myeloid, Acute
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low dose cytarabine in patients >= 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive…
- Trial name
- NCT01721876
- Testing
- Volasertib, Cytarabine
- Where
- 122 sites in United States, Argentina and 23 more
- Volunteers
- 666 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.